Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH2722 injection in atopic dermatitis (phase 2)
CTR20230796Phase 2Completed
- Sponsor
- Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQH2722 in atopic dermatitis (AD), sponsored by Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Started Mar 2023; status: completed.
02
Drugs
TQH2722
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20230796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230796.